Min Li

Dr. Min Li

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in World Neurosurgery
Verified
Journal Article
Closed access
MLMin Li
Min Li
XGXiaogang Gao
Xiaogang Gao
GRGary B. Rajah
Gary B. Rajah
JLJiantao Liang
Jiantao Liang
JCJian Chen
Jian Chen
Ran MengRan Meng
Ran Meng

1 April 2018 in Veterinary Parasitology
Verified
Journal Article
Closed access
JWJiawei Wang
Jiawei Wang
Jilei ZhangJilei Zhang
Jilei Zhang
PKPat Kelly
Pat Kelly
XZXiaofeng Zheng
Xiaofeng Zheng
MLMin Li
Min Li
Chengming WangChengming Wang
Chengming Wang

28 September 2012 in Peptides
Verified
Journal Article
Closed access
AKAltaf-M. Khan
Altaf-M. Khan
MLMin Li
Min Li
SASolange Abdulnour-Nakhoul
Solange Abdulnour-Nakhoul
JMJerome L. Maderdrut
Jerome L. Maderdrut
ESEric E. Simon
Eric E. Simon
VBVecihi Batuman
Vecihi Batuman

25 January 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
XYXiuheng Yu
Xiuheng Yu
XZXiaodan Zhou
Xiaodan Zhou
MLMin Li
Min Li
YZYu Chen Zhao
Yu Chen Zhao
This study investigated the patterns of hematological adverse events related to daptomycin (DAP), tigecycline (TIG), vancomycin (VAN) and linezolid (LIN) in the FDA Adverse Event Reporting System (FAERS). Adverse event associations were analyzed through calculating reporting odds ratio (ROR), proportional reporting ratio (PRR), multiple gamma Poisson shrinkage (MGPS), and Bayesian confidence propagation neural network (BCPNN). A comprehensive descriptive analysis was also conducted considering factors such as age, gender, daily dose, cumulative dose, and time to onset. The leading hematologic adverse events were eosinophilia for daptomycin, coagulation abnormalities and thrombocytopenia for tigecycline, thrombocytopenia, neutropenia, and anemia for linezolid, and thrombocytopenia, eosinophilia, and neutropenia for vancomycin. Most of the affected patients were over 55 years old. Daily doses for the tigecycline and daptomycin groups exceeded the standard daily dose. The times to onset were 14.00 days for daptomycin (interquartile range [IQR], 4.00-21.00), 6.00 days for tigecycline (IQR, 2.00-9.00), 10.00 days for linezolid (IQR, 4.00-16.5), and 10.00 days for vancomycin (IQR,5.00-20.00). It is essential to intensify early monitoring and identification of these adverse events, especially in the context of off-label dosages and for elderly patients and individuals taking medication for over one week.

13 November 2015 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JLjingyao liu
jingyao liu
MLMin Li
Min Li
GLGuibo Li
Guibo Li
CZChunkui Zhou
Chunkui Zhou
RZRensheng Zhang
Rensheng Zhang
This study describes the case of a 41-year-old woman admitted for anterograde memory loss, right facial grimacing and right arm posturing that had begun 1 month previously. Cranial magnetic resonance-diffusion weighted imaging and -fluid-attenuated inversion recovery imaging revealed a hyperintense signal in the left hippocampus and right basal ganglia, but no contrast enhancement. An electroencephalogram revealed rhythmic sharp and slow waves and rhythmic θ build-ups in the left temporal area. Single-photon emission computed tomography showed increased regional blood flow perfusion in the left cerebral frontal lobe and the right basal ganglia. The cerebrospinal fluid was normal, with the exception of the presence of leucine-rich glioma-inactivated 1 (LGI1) antibodies, and LGI1 antibodies were also found in the blood serum. The presence of the antibodies, the faciobrachial dystonic seizures (FBDSs) and the memory loss indicated limbic encephalitis. After 3 months of immunotherapy, the patient was free from epileptic seizures and had undergone a partial memory restoration. FBDSs alone justify the immediate initiation of immunotherapy, even prior to laboratory confirmation of the disease, as early treatment limits the duration of the illness.

22 December 2025 in Revista De Neurologia
Verified
Journal Article
Open access
PDF file
SWShuling Wan
Shuling Wan
Xunming JiXunming Ji
Xunming Ji
Ran MengRan Meng
Ran Meng
MLMin Li
Min Li
Intracerebral hemorrhage (ICH) is a devastating stroke subtype with high morbidity and mortality. Beyond primary injury from blood extravasation, secondary injury driven by erythrocyte lysis and its toxic degradation products exacerbates inflammation, oxidative stress, and neuronal damage. Accelerating endogenous hematoma resolution, including the removal of erythrocytes and their byproducts, represents a promising therapeutic strategy. This review systematically delineates three key mechanisms of hematoma resolution post-ICH: (1) erythrophagocytosis by microglia/macrophages through Tyro3, Axl, and Mertk (TAM) receptors, the cluster of differentiation (CD) 36 receptor, the triggering receptor expressed on myeloid cells 2, and the signal regulatory protein α receptor; (2) clearance of hemolytic products through the hemoglobin-haptoglobin-CD163 and hemin-hemopexin-CD91 axes; and (3) glymphatic and meningeal lymphatic drainage. Pharmacological, genetic, and physical interventions targeting these pathways have demonstrated potential to enhance phagocytosis, promote glymphatic and meningeal lymphatic function, accelerate hematoma resolution, and improve neurological outcomes in ICH models. By leveraging the intrinsic clearance mechanisms of the intracerebral hematoma, this review highlights promising therapeutic targets and strategies to overcome current clinical limitations and demonstrates significant translational potential.